BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 17408237)

  • 1. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.
    Bauer RJ; Guzy S; Ng C
    AAPS J; 2007 Mar; 9(1):E60-83. PubMed ID: 17408237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of different population pharmacokinetic algorithms.
    Colucci P; Grenier J; Yue CS; Turgeon J; Ducharme MP
    Ther Drug Monit; 2011 Oct; 33(5):583-91. PubMed ID: 21912327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.
    Dartois C; Brendel K; Comets E; Laffont CM; Laveille C; Tranchand B; Mentré F; Lemenuel-Diot A; Girard P
    Br J Clin Pharmacol; 2007 Nov; 64(5):603-12. PubMed ID: 17711538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models.
    Liu X; Wang Y
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):359-70. PubMed ID: 27215925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
    Bazzoli C; Retout S; Mentré F
    Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the nonparametric estimation method in NONMEM VI.
    Savic RM; Kjellsson MC; Karlsson MO
    Eur J Pharm Sci; 2009 Apr; 37(1):27-35. PubMed ID: 19159684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software.
    Farenc C; Fabreguette JR; Bressolle F
    Comput Biomed Res; 2000 Oct; 33(5):315-29. PubMed ID: 11017724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of uncertainty parameters estimated by different population PK software and methods.
    Dartois C; Lemenuel-Diot A; Laveille C; Tranchand B; Tod M; Girard P
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):289-311. PubMed ID: 17216368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to handling pharmacodynamic baseline responses.
    Dansirikul C; Silber HE; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):269-83. PubMed ID: 18446428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel.
    Zhang Y; Huo M; Zhou J; Xie S
    Comput Methods Programs Biomed; 2010 Sep; 99(3):306-14. PubMed ID: 20176408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations.
    Tornøe CW; Agersø H; Jonsson EN; Madsen H; Nielsen HA
    Comput Methods Programs Biomed; 2004 Oct; 76(1):31-40. PubMed ID: 15313540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An implementation of the Expectation-Maximisation (EM) algorithm for population pharmacokinetic-pharmacodynamic modelling in ACSLXTREME.
    Yates JW
    Comput Methods Programs Biomed; 2009 Oct; 96(1):49-62. PubMed ID: 19410328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics.
    Dodds MG; Vicini P
    Ann Biomed Eng; 2004 Sep; 32(9):1300-13. PubMed ID: 15493516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.
    Lindbom L; Ribbing J; Jonsson EN
    Comput Methods Programs Biomed; 2004 Aug; 75(2):85-94. PubMed ID: 15212851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fast method for testing covariates in population PK/PD Models.
    Khandelwal A; Harling K; Jonsson EN; Hooker AC; Karlsson MO
    AAPS J; 2011 Sep; 13(3):464-72. PubMed ID: 21725709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.
    Baverel PG; Savic RM; Wilkins JJ; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):297-315. PubMed ID: 19572188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the performance of first-order conditional estimation (FOCE) and different expectation-maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model.
    Bach T; An G
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):581-595. PubMed ID: 33884580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE; Tett SE
    Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.